Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded shares of Zevra Therapeutics (NASDAQ:ZVRA - Free Report) from a strong-buy rating to a buy rating in a research report report published on Sunday morning.

A number of other analysts have also recently commented on ZVRA. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Cantor Fitzgerald upped their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Finally, HC Wainwright began coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Stock Up 1.6%

Shares of ZVRA traded up $0.19 on Friday, reaching $11.77. The stock had a trading volume of 1,007,575 shares, compared to its average volume of 743,934. The firm has a market capitalization of $643.58 million, a price-to-earnings ratio of -6.19 and a beta of 1.97. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. The company has a 50-day simple moving average of $9.76 and a 200-day simple moving average of $8.41. Zevra Therapeutics has a 12-month low of $5.45 and a 12-month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. The company had revenue of $20.40 million during the quarter, compared to analysts' expectations of $16.96 million. During the same quarter last year, the business posted ($0.40) EPS. Sell-side analysts predict that Zevra Therapeutics will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in Zevra Therapeutics during the 4th quarter worth $53,000. GAMMA Investing LLC boosted its position in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after acquiring an additional 8,020 shares in the last quarter. Strs Ohio bought a new stake in Zevra Therapeutics during the 1st quarter valued at $125,000. Squarepoint Ops LLC boosted its position in Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after acquiring an additional 4,384 shares in the last quarter. Finally, ProShare Advisors LLC bought a new stake in Zevra Therapeutics during the 4th quarter valued at $145,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.